Juno Therapeutics Inc (NASDAQ:JUNO) Director Richard Klausner sold 12,724 shares of Juno Therapeutics stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $48.21, for a total transaction of $613,424.04. Following the sale, the director now owns 741,499 shares of the company’s stock, valued at approximately $35,747,666.79. The sale was disclosed in a document filed with the SEC, which is available through this link.
Richard Klausner also recently made the following trade(s):
- On Thursday, December 21st, Richard Klausner sold 36,000 shares of Juno Therapeutics stock. The stock was sold at an average price of $44.76, for a total transaction of $1,611,360.00.
Juno Therapeutics Inc (NASDAQ:JUNO) opened at $69.25 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics Inc has a 52-week low of $18.90 and a 52-week high of $70.00. The stock has a market capitalization of $7,910.00, a price-to-earnings ratio of -20.43 and a beta of 2.32.
Several institutional investors have recently modified their holdings of JUNO. The Manufacturers Life Insurance Company lifted its holdings in shares of Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares in the last quarter. Pacad Investment Ltd. bought a new stake in shares of Juno Therapeutics in the second quarter valued at about $105,000. Advisor Group Inc. raised its holdings in Juno Therapeutics by 141.1% during the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,439 shares in the last quarter. QS Investors LLC bought a new stake in Juno Therapeutics during the second quarter worth about $135,000. Finally, Bronfman E.L. Rothschild L.P. raised its holdings in Juno Therapeutics by 27,376.9% during the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 3,559 shares in the last quarter. Institutional investors own 69.94% of the company’s stock.
JUNO has been the subject of a number of research analyst reports. Morgan Stanley restated an “equal weight” rating and set a $43.00 price objective (up from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Goldman Sachs Group reissued a “neutral” rating and set a $44.00 price target on shares of Juno Therapeutics in a research report on Friday, October 6th. Maxim Group reissued a “buy” rating and set a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a report on Monday, October 9th. Cowen reissued a “buy” rating and set a $49.00 price target on shares of Juno Therapeutics in a research report on Friday, October 27th. Finally, Citigroup reaffirmed a “buy” rating and issued a $59.00 target price on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. Juno Therapeutics currently has an average rating of “Hold” and a consensus price target of $49.89.
TRADEMARK VIOLATION WARNING: This report was first published by BBNS and is owned by of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://baseballnewssource.com/markets/richard-klausner-sells-12724-shares-of-juno-therapeutics-inc-juno-stock/1824546.html.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.